Exelixis Reports $2.1B Cabozantinib Sales, FDA Accepts Zanzalintinib NDA
Exelixis recorded US cabozantinib franchise revenues of $2.1 billion in fiscal 2025 and secured FDA acceptance of its zanzalintinib plus atezolizumab New Drug Application for treated metastatic colorectal cancer. The company targets a December 2026 FDA decision to establish zanzalintinib as a second major oncology franchise.
1. Fiscal 2025 Cabozantinib Revenues
Exelixis reported US net product revenues of $2.1 billion from its cabozantinib franchise in fiscal 2025, underscoring strong demand for its leading oncology therapy.
2. FDA Acceptance of Zanzalintinib NDA
The FDA has accepted Exelixis’s New Drug Application for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer, with a target action date set for December 2026 to potentially launch a second oncology franchise.
Related News
LCLN
Lincoln International Debuts 12.6% Up, Valued at $2.3 Billion After $421M IPO
LCLN•
MSFT
Microsoft’s AI Spending Drives 50% of Nvidia’s $38 B Data Center Revenue
MSFT•
UXIN
Uxin to Launch 5,000-Vehicle Chongqing Superstore in 2026 Expansion Drive
UXIN•
WPM
Wheaton Precious Metals Publishes Report Highlighting $9.4M Community Investment and MSCI AAA Rating
WPM•
C
SpaceX Reveals $1.45B Bitcoin Stake Ahead of $1.75T IPO
C•
Sources
ZF